Immix Biopharma (IMMX) Competitors $1.98 -0.01 (-0.50%) Closing price 02/14/2025 04:00 PM EasternExtended Trading$1.98 0.00 (0.00%) As of 02/14/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMMX vs. CGEN, LRMR, AMRN, CTNM, VIRI, ZYBT, DRUG, MOLN, SLRN, and OCGNShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Compugen (CGEN), Larimar Therapeutics (LRMR), Amarin (AMRN), Contineum Therapeutics (CTNM), Virios Therapeutics (VIRI), Zhengye Biotechnology (ZYBT), Bright Minds Biosciences (DRUG), Molecular Partners (MOLN), Acelyrin (SLRN), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Compugen Larimar Therapeutics Amarin Contineum Therapeutics Virios Therapeutics Zhengye Biotechnology Bright Minds Biosciences Molecular Partners Acelyrin Ocugen Compugen (NASDAQ:CGEN) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends. Is CGEN or IMMX more profitable? Compugen has a net margin of 2.67% compared to Immix Biopharma's net margin of 0.00%. Compugen's return on equity of 2.62% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Compugen2.67% 2.62% 1.36% Immix Biopharma N/A -102.68%-80.89% Does the media favor CGEN or IMMX? In the previous week, Immix Biopharma had 2 more articles in the media than Compugen. MarketBeat recorded 2 mentions for Immix Biopharma and 0 mentions for Compugen. Immix Biopharma's average media sentiment score of 0.49 beat Compugen's score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Compugen Neutral Immix Biopharma Neutral Do analysts rate CGEN or IMMX? Compugen presently has a consensus target price of $4.00, suggesting a potential upside of 80.18%. Immix Biopharma has a consensus target price of $7.00, suggesting a potential upside of 253.54%. Given Immix Biopharma's higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, CGEN or IMMX? Compugen has a beta of 2.65, suggesting that its share price is 165% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Does the MarketBeat Community prefer CGEN or IMMX? Compugen received 298 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 64.38% of users gave Compugen an outperform vote. CompanyUnderperformOutperformCompugenOutperform Votes30964.38% Underperform Votes17135.63% Immix BiopharmaOutperform Votes11100.00% Underperform VotesNo Votes Which has higher earnings and valuation, CGEN or IMMX? Immix Biopharma has lower revenue, but higher earnings than Compugen. Immix Biopharma is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$33.46M5.92-$18.75M$0.02111.00Immix BiopharmaN/AN/A-$15.43M-$0.85-2.33 Do insiders and institutionals hold more shares of CGEN or IMMX? 12.2% of Compugen shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 48.9% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryCompugen beats Immix Biopharma on 10 of the 16 factors compared between the two stocks. Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.47M$6.83B$5.75B$9.22BDividend YieldN/A2.90%5.27%3.99%P/E Ratio-2.339.3425.7019.43Price / SalesN/A324.30468.6281.02Price / CashN/A75.4646.0638.90Price / Book2.445.537.305.05Net Income-$15.43M$123.46M$3.19B$222.81M7 Day Performance0.51%1.37%1.69%1.29%1 Month Performance-2.94%2.09%4.13%1.52%1 Year Performance-37.93%1.28%22.24%16.53% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma3.2666 of 5 stars$1.98-0.5%$7.00+253.5%-37.9%$54.47MN/A-2.339Gap DownCGENCompugen1.5969 of 5 stars$2.42-5.8%$4.00+65.3%-7.5%$215.96M$33.46M121.0070LRMRLarimar Therapeutics1.5339 of 5 stars$3.37-2.6%$20.13+497.2%-73.9%$215.04MN/A-2.9330AMRNAmarin0.2295 of 5 stars$0.52-3.3%N/A-49.4%$214.95M$306.91M-5.82360Analyst RevisionCTNMContineum Therapeutics2.9587 of 5 stars$8.25-1.9%$29.25+254.5%N/A$212.67M$50M0.0031Short Interest ↓News CoverageVIRIVirios Therapeutics0.1653 of 5 stars$10.74-9.1%$3.00-72.1%+1,492.2%$206.83MN/A-39.785Gap DownZYBTZhengye BiotechnologyN/A$4.35+3.3%N/AN/A$205.19MN/A0.00N/AQuiet Period ExpirationDRUGBright Minds Biosciences4.2605 of 5 stars$46.29+5.3%$84.33+82.2%+2,043.6%$205.07MN/A-92.58N/AEarnings ReportShort Interest ↓MOLNMolecular Partners0.1388 of 5 stars$5.07+2.1%N/A+5.7%$204.79M$7.84M-2.36180Gap UpSLRNAcelyrin2.824 of 5 stars$1.89-7.4%$9.60+407.9%-74.5%$204.67MN/A-0.77135High Trading VolumeOCGNOcugen1.6518 of 5 stars$0.70-1.7%$5.67+709.5%-24.4%$203.92M$6.04M-3.8980Analyst Revision Related Companies and Tools Related Companies Compugen Competitors Larimar Therapeutics Competitors Amarin Competitors Contineum Therapeutics Competitors Virios Therapeutics Competitors Zhengye Biotechnology Competitors Bright Minds Biosciences Competitors Molecular Partners Competitors Acelyrin Competitors Ocugen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMMX) was last updated on 2/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
